PTPRB
PTPRB (Receptor-type tyrosine-protein phosphatase beta) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Mesothelioma, Skin cancer and 5 more.
Overview
Plays an important role in blood vessel remodeling and angiogenesis. Not necessary for the initial formation of blood vessels, but is essential for their maintenance and remodeling. Can induce dephosphorylation of TEK/TIE2, CDH5/VE-cadherin and KDR/VEGFR-2.
CIViC holds 4 clinical evidence items and 0 assertions across 3 variants, naming Sunitinib and Vatalanib. Open Targets scores its association with cancer at 0.71 (direct and indirect evidence; datatypes literature 0.80, genetic association 0.03, somatic mutation 0.92). IntOGen calls it a driver in 6 cohorts (1 activating, 5 loss-of-function), covering Angiosarcoma, Melanoma, Ovarian Epithelial Tumour, Pleural Mesothelioma, Thymoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · PTPRB (Receptor-type tyrosine-protein phosphatase beta) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Mesothelioma, Skin cancer and 5 more.
- 1 · What it is
PTPRB (Receptor-type tyrosine-protein phosphatase beta) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Ovarian cancer, Mesothelioma, Skin cancer and 5 more.
- 2 · What goes wrong in cancer
Plays an important role in blood vessel remodeling and angiogenesis. Not necessary for the initial formation of blood vessels, but is essential for their maintenance and remodeling.
- 3 · How drugs use it
No product in this corpus aims at PTPRB yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:9665 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P23467 (protein name, function text, keywords and locations (REST API)); CIViC gene PTPRB (4 evidence items, 0 assertions, 3 variants; diseases: Angiosarcoma (GraphQL API, CC0)); Open Targets ENSG00000127329 (association with cancer (MONDO_0004992) 0.71; per-cancer scores at or above 0.5: melanoma 0.59, sarcoma 0.52, skin cancer 0.57, breast cancer 0.52, lung cancer 0.53 (GraphQL API, CC0)); IntOGen PTPRB (driver in 6 cohorts (Act 1, LoF 5); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Plays an important role in blood vessel remodeling and angiogenesis. Not necessary for the initial formation of blood vessels, but is essential for their maintenance and remodeling. Can induce dephosphorylation of TEK/TIE2, CDH5/VE-cadherin and KDR/VEGFR-2. Regulates angiopoietin-TIE2 signalling in endothelial cells. Acts as a negative regulator of TIE2, and controls TIE2 driven endothelial cell proliferation, which in turn affects blood vessel remodeling during embryonic development and determines blood vessel size during perinatal growth. Essential for the maintenance of endothelial cell contact integrity and for the adhesive function of VE-cadherin in endothelial cells and this requires the presence of plakoglobin. Location: Membrane (UniProt). Locus 12q15 (HGNC).
- Ovarian cancer: IntOGen driver in 2 cohorts (OVT)
- Mesothelioma: IntOGen driver in 1 cohort (PLMESO)
- Skin cancer: Open Targets association 0.57 with skin cancer (MONDO_0002898)
- Lung cancer: Open Targets association 0.53 with lung cancer (MONDO_0008903)
- Sarcomas: Open Targets association 0.52 with sarcoma (MONDO_0005089)
- Breast cancer: Open Targets association 0.52 with breast cancer (MONDO_0007254)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 5 cohorts; CIViC holds 4 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"PTPRB" OR ABSTRACT:"PTPRB" OR TITLE:"protein tyrosine phosphatase receptor type B" OR ABSTRACT:"protein tyrosine phosphatase receptor type B" OR TITLE:"Receptor-type tyrosine-protein phosphatase beta" OR ABSTRACT:"Receptor-type tyrosine-protein phosphatase beta") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PTPRB, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCBLB
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetPIK3CB
Shares Lung cancer (all types), Skin cancer (all types), Sarcomas (soft tissue, bone, GIST), Breast cancer (all types).
- TargetMECOM
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetPOT1
Shares Lung cancer (all types), Skin cancer (all types), Sarcomas (soft tissue, bone, GIST), Breast cancer (all types).
- TargetPRDM16
Shares Lung cancer (all types), Skin cancer (all types), Sarcomas (soft tissue, bone, GIST), Breast cancer (all types).
- TargetPLCG1
Shares Angiosarcoma, Skin cancer (all types), Sarcomas (soft tissue, bone, GIST), CIViC.
- TargetRAD51B
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.
- TargetSMAD3
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), CIViC.